152 related articles for article (PubMed ID: 8474480)
1. Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors.
Gomez-Mancilla B; Boucher R; Gagnon C; Di Paolo T; Markstein R; Bédard PJ
Mov Disord; 1993 Apr; 8(2):144-50. PubMed ID: 8474480
[TBL] [Abstract][Full Text] [Related]
2. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
3. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Pearce RK; Banerji T; Jenner P; Marsden CD
Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
[TBL] [Abstract][Full Text] [Related]
4. Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
Rouillard C; Bédard PJ; Di Paolo T
Eur J Pharmacol; 1990 Aug; 185(2-3):209-15. PubMed ID: 2253695
[TBL] [Abstract][Full Text] [Related]
5. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
Bédard PJ; Gomez-Mancilla B; Blanchette P; Gagnon C; Falardeau P; DiPaolo T
Adv Neurol; 1993; 60():113-8. PubMed ID: 8093573
[No Abstract] [Full Text] [Related]
6. The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
Nomoto M; Fukuda T
Adv Neurol; 1993; 60():119-22. PubMed ID: 8093574
[No Abstract] [Full Text] [Related]
7. Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism.
Gomez-Mancilla B; Boucher R; Bédard PJ
Mov Disord; 1992; 7(1):43-7. PubMed ID: 1348351
[TBL] [Abstract][Full Text] [Related]
8. Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors.
Gagnon C; Gomez-Mancilla B; Markstein R; Bédard PJ; Di Paolo T
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jul; 19(4):667-76. PubMed ID: 8588064
[TBL] [Abstract][Full Text] [Related]
9. Effects of a selective partial D1 agonist, CY 208-243, in de novo patients with Parkinson disease.
Emre M; Rinne UK; Rascol A; Lees A; Agid Y; Lataste X
Mov Disord; 1992; 7(3):239-43. PubMed ID: 1535688
[TBL] [Abstract][Full Text] [Related]
10. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
Gomez-Mancilla B; Bédard PJ
J Pharmacol Exp Ther; 1991 Oct; 259(1):409-13. PubMed ID: 1681090
[TBL] [Abstract][Full Text] [Related]
11. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
Yoshimura N; Mizuta E; Yoshida O; Kuno S
J Pharmacol Exp Ther; 1998 Jul; 286(1):228-33. PubMed ID: 9655864
[TBL] [Abstract][Full Text] [Related]
13. Enhanced neuroprotective effect by combination of bromocriptine and Hypericum perforatum extract against MPTP-induced neurotoxicity in mice.
Mohanasundari M; Srinivasan MS; Sethupathy S; Sabesan M
J Neurol Sci; 2006 Nov; 249(2):140-4. PubMed ID: 16876826
[TBL] [Abstract][Full Text] [Related]
14. Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors.
Gagnon C; Gomez-Mancilla B; Bédard PJ; Di Paolo T
Neurosci Lett; 1993 Nov; 163(1):31-5. PubMed ID: 7905197
[TBL] [Abstract][Full Text] [Related]
15. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
Blanchet PJ; Grondin R; Bédard PJ
Mov Disord; 1996 Jan; 11(1):91-4. PubMed ID: 8771074
[TBL] [Abstract][Full Text] [Related]
16. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys.
Gomez-Mancilla B; Bédard PJ
Exp Neurol; 1992 Aug; 117(2):185-8. PubMed ID: 1354166
[TBL] [Abstract][Full Text] [Related]
17. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
Smith L; De Salvia M; Jenner P; Marsden CD
Mov Disord; 1996 Mar; 11(2):125-35. PubMed ID: 8684381
[TBL] [Abstract][Full Text] [Related]
18. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
[TBL] [Abstract][Full Text] [Related]
19. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
Mov Disord; 2006 Jan; 21(1):9-17. PubMed ID: 16127720
[TBL] [Abstract][Full Text] [Related]
20. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]